Salpingectomy in individuals at high risk for tubo-ovarian cancer - consensus and precaution - Articles - Oncology · Hematology

Breast Cancer

Tailoring Treatment to Cancer Risk and Patient Preference: The 2025 St Gallen International Breast Cancer Consensus Statement on Individualizing Therapy for Patients With Early Breast Cancer

Ann Oncol

Burstein HJ, Curigliano G, Gnant M, Loibl S, Regan MM, Loi S, Denkert C, Poortmans P, Cameron D, Thurlimann B, Weber WP, Panelists of the St. Gallen International Breast Cancer Consensus 2025

doi: 10.1016/j.annonc.2025.09.007

Gastrointestinal Cancer

Risk-stratified surveillance for individuals in the UK at high risk of developing pancreatic cancer: Outcomes from the European Registry of Hereditary Pancreatic Diseases (EUROPAC)

Eur J Cancer

Hopley PJ, Peysner R, Boughey A, Kewlani B, Smith AM, Aithal GP, Oppong KW, Finch-Jones M, Hamady Z, Athwal TS, Milburn J, Menon S, Chapman M, Pereira SP, Taylor M, Shingler G, Briggs C, Ghaneh P, Costello E, Greenhalf W, Halloran CM

doi: 10.1016/j.ejca.2026.116592

Lung, Respiratory and Thoracic Cancer

Polygenic risk score to define risk of cancer-associated thrombosis among patients with lung cancer in a population-based study

Lung Cancer

Tafur A, Sebai A, Shi Z, Wei J, Tran H, Zheng SL, Krantz S, Hensing T, Mansfield AS, Xu J

doi: 10.1016/j.lungcan.2025.108712

Gynecologic Cancer

Thyroid hormones and epithelial ovarian cancer risk and survival: results from the EPIC study

J Natl Cancer Inst

Majidi A, Rinaldi S, Biessy C, Vozar B, Truong T, Turzanski Fortner R, Le Cornet C, Schulze MB, Panico C, Tumino R, Masala G, Ricceri F, Vener C, Sánchez MJ, Zamora-Ros R, Crous-Bou M, Colorado-Yohar SM, Guevara M, Israelsson P, Travis R, Riboli E, Fournier A, Dossus L

doi: 10.1093/jnci/djaf222

Gynecologic Cancer

Pre-diagnosis thyroid dysfunction and ovarian cancer risk and survival: a prospective cohort study

J Natl Cancer Inst

Majidi A, Rinaldi S, Truong T, Dossus L, Fournier A

doi: 10.1093/jnci/djag055

ESMO 2025

Breast Cancer

monarchE: Abemaciclib plus ET versus ET alone shows proven OS benefit in patients with HR+/HER2− node-positive, high-risk early breast cancer

Further Publications

NCCN Guidelines® Insights: Genetic/Familial High-Risk Assessment: Breast, Ovarian, Pancreatic, and Prostate, Version 2.2026

J Natl Compr Canc Netw

Cheng HH, Giri VN, Goggins M, Yurgelun MB, Karlan BY, Norquist BS, Daly MB, Pal T, AlHilli Z, Arun B, Churpek J, Colonna S, Domchek SM, Escobar MR, Fejerman L, Friedman S, Hagemann A, Hendrix A, Huo D, Hutton ML, Kassem N, Khan S, Kurian AW, Laronga C, Mak JS, Maxwell KN, McDonnell K, Merajver SD, Mersch J, Offit K, Plichta J, Rash D, Reiser G, Senter-Jamieson L, Shannon KM, Welborn J, Wick MJ, Wood M, Darlow S, Diwan Z, Dwyer M

doi: 10.6004/jnccn.2026.0007

Gynecologic Cancer

Risk of ovarian cancer in women with a pathogenic or likely pathogenic variant in NBN: a systematic review and meta-analysis

Am J Obstet Gynecol

Ganesan S, Mansour L, Dibden A, Sideris M, Malan A, Oxley S, Kalra A, Sia J, Wei X, Deshmukh P, Mohamed H, Morgan RD, Flaum N, Brentnall A, Fierheller CT, Evans DG, Manchanda R

doi: 10.1016/j.ajog.2026.02.020

ESMO 2025

Breast Cancer

Related content

Tailoring Treatment to Cancer Risk and Patient Preference: The 2025 St Gallen International Breast Cancer Consensus Statement on Individualizing Therapy for Patients With Early Breast Cancer

Risk-stratified surveillance for individuals in the UK at high risk of developing pancreatic cancer: Outcomes from the European Registry of Hereditary Pancreatic Diseases (EUROPAC)

Polygenic risk score to define risk of cancer-associated thrombosis among patients with lung cancer in a population-based study

Thyroid hormones and epithelial ovarian cancer risk and survival: results from the EPIC study

Pre-diagnosis thyroid dysfunction and ovarian cancer risk and survival: a prospective cohort study

monarchE: Abemaciclib plus ET versus ET alone shows proven OS benefit in patients with HR+/HER2− node-positive, high-risk early breast cancer

NCCN Guidelines® Insights: Genetic/Familial High-Risk Assessment: Breast, Ovarian, Pancreatic, and Prostate, Version 2.2026

Risk of ovarian cancer in women with a pathogenic or likely pathogenic variant in NBN: a systematic review and meta-analysis

DESTINY-Breast11: Neoadjuvant T-DXd plus THP significantly improves pCR in high-risk HER2-positive early breast cancer